JPWO2020172528A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172528A5 JPWO2020172528A5 JP2021549227A JP2021549227A JPWO2020172528A5 JP WO2020172528 A5 JPWO2020172528 A5 JP WO2020172528A5 JP 2021549227 A JP2021549227 A JP 2021549227A JP 2021549227 A JP2021549227 A JP 2021549227A JP WO2020172528 A5 JPWO2020172528 A5 JP WO2020172528A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variants
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 347
- 238000006467 substitution reaction Methods 0.000 claims description 116
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 8
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 102000007562 Serum Albumin Human genes 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000003675 cytokine receptors Human genes 0.000 claims description 4
- 108010057085 cytokine receptors Proteins 0.000 claims description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 2
- 102100034231 Cell surface A33 antigen Human genes 0.000 claims description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims description 2
- 102000012804 EPCAM Human genes 0.000 claims description 2
- 101150084967 EPCAM gene Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000996823 Homo sapiens Cell surface A33 antigen Proteins 0.000 claims description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101710123134 Ice-binding protein Proteins 0.000 claims description 2
- 101710082837 Ice-structuring protein Proteins 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 241000282560 Macaca mulatta Species 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 102100023123 Mucin-16 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 239000006207 intravenous dosage form Substances 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 239000006201 parenteral dosage form Substances 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809475P | 2019-02-22 | 2019-02-22 | |
| US62/809,475 | 2019-02-22 | ||
| PCT/US2020/019215 WO2020172528A1 (en) | 2019-02-22 | 2020-02-21 | Albumin binding antibodies and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520998A JP2022520998A (ja) | 2022-04-04 |
| JPWO2020172528A5 true JPWO2020172528A5 (enExample) | 2023-02-28 |
Family
ID=72144485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549227A Pending JP2022520998A (ja) | 2019-02-22 | 2020-02-21 | アルブミン結合抗体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12479909B2 (enExample) |
| EP (1) | EP3927740A4 (enExample) |
| JP (1) | JP2022520998A (enExample) |
| CN (1) | CN113508134B (enExample) |
| TW (1) | TW202045545A (enExample) |
| WO (1) | WO2020172528A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR20210022004A (ko) * | 2018-06-18 | 2021-03-02 | 안위타 바이오사이언시스, 인코포레이티드 | 항-메소텔린 작제물 및 이의 용도 |
| WO2021102063A1 (en) | 2019-11-20 | 2021-05-27 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
| WO2021222150A2 (en) | 2020-04-28 | 2021-11-04 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| TW202221019A (zh) | 2020-07-30 | 2022-06-01 | 美商安維塔生物科學股份有限公司 | 介白素-22融合蛋白及其藥物組合物及治療應用 |
| EP4192959A4 (en) * | 2020-10-02 | 2024-10-30 | Agency for Science, Technology and Research | EXPRESSION SYSTEM FOR PROTEIN PRODUCTION AND SCREENING |
| JP2023549537A (ja) * | 2020-11-16 | 2023-11-27 | エイビー セラピューティクス インコーポレイテッド | 多重特異性抗体およびその使用方法 |
| CA3201560A1 (en) * | 2020-12-08 | 2022-06-16 | David Campbell | Half-life extending compositions and methods |
| CN117545504A (zh) * | 2021-06-07 | 2024-02-09 | 上海济煜医药科技有限公司 | 抗人血清白蛋白的抗原结合蛋白 |
| CN119137148A (zh) * | 2022-05-05 | 2024-12-13 | 印希比生物科学有限公司 | 结合白蛋白的多肽及其用途 |
| WO2024038112A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
| WO2024051796A1 (en) * | 2022-09-09 | 2024-03-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Albumin binding proteins, fusion proteins and uses thereof |
| WO2024097639A1 (en) * | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
| AR131869A1 (es) | 2023-02-17 | 2025-05-07 | Ablynx Nv | POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL |
| WO2024236068A1 (en) * | 2023-05-17 | 2024-11-21 | Navigo Proteins | Affinity ligand for a single chain antibody fragment specific for serum albumin |
| NL2036011B1 (en) | 2023-10-12 | 2025-04-30 | Synapse Res Institute | Molecules for reversing anti-coagulant activity of direct oral anticoagulants |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003286002B2 (en) * | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| EP2692736B1 (en) | 2008-10-14 | 2018-04-18 | National Research Council Of Canada | Bsa-specific antibodies |
| SG177601A1 (en) * | 2009-07-16 | 2012-02-28 | Glaxo Group Ltd | Improved anti-serum albumin binding single variable domains |
| US9556273B2 (en) * | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| EA201390116A1 (ru) * | 2010-08-20 | 2013-09-30 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Улучшенные связывающие варианты против сывороточного альбумина |
| EP2807189B1 (en) * | 2012-01-23 | 2019-03-20 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| CN119192402A (zh) * | 2012-02-15 | 2024-12-27 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| WO2016034968A1 (en) * | 2014-09-02 | 2016-03-10 | Pfizer Inc. | Therapeutic antibody |
| JP6859259B2 (ja) * | 2014-11-19 | 2021-04-14 | ジェネンテック， インコーポレイテッド | ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用 |
| KR20190080992A (ko) * | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| US11142569B2 (en) | 2015-11-13 | 2021-10-12 | Ablynx N.V. | Serum albumin-binding immunoglobulin variable domains |
| EP3493844A4 (en) * | 2016-05-20 | 2021-03-24 | Harpoon Therapeutics Inc. | SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN |
| IL310340A (en) * | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| SG10202107880XA (en) * | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| TN2020000015A1 (en) * | 2017-08-03 | 2021-10-04 | Amgen Inc | Interleukin-21 muteins and methods of treatment |
| CA3076250A1 (en) * | 2017-10-02 | 2019-04-11 | Vib Vzw | Compounds to inhibit bacterial s-layer protein assembly |
| KR20210022004A (ko) | 2018-06-18 | 2021-03-02 | 안위타 바이오사이언시스, 인코포레이티드 | 항-메소텔린 작제물 및 이의 용도 |
| WO2021102063A1 (en) * | 2019-11-20 | 2021-05-27 | Anwita Biosciences, Inc. | Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications |
| TW202221019A (zh) * | 2020-07-30 | 2022-06-01 | 美商安維塔生物科學股份有限公司 | 介白素-22融合蛋白及其藥物組合物及治療應用 |
-
2020
- 2020-02-21 WO PCT/US2020/019215 patent/WO2020172528A1/en not_active Ceased
- 2020-02-21 EP EP20759885.5A patent/EP3927740A4/en not_active Withdrawn
- 2020-02-21 TW TW109105677A patent/TW202045545A/zh unknown
- 2020-02-21 JP JP2021549227A patent/JP2022520998A/ja active Pending
- 2020-02-21 US US17/432,488 patent/US12479909B2/en active Active
- 2020-02-21 CN CN202080015296.8A patent/CN113508134B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7591917B2 (ja) | Ｓｉｒｐ－アルファドメインまたはそのバリアントを有する構築物 | |
| JPWO2020172528A5 (enExample) | ||
| US10047163B2 (en) | Multispecific constructs | |
| US20160009824A1 (en) | Tetravalent bispecific antibodies | |
| ES2967739T3 (es) | Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA | |
| RU2015140917A (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
| RU2019123613A (ru) | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 | |
| JP2023540799A (ja) | 多重特異性免疫標的化分子及びその使用 | |
| CN113480656A (zh) | 抗ror1抗体 | |
| RU2015140915A (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
| JP7356726B2 (ja) | タンパク性ヘテロ二量体及びその使用 | |
| KR20170036503A (ko) | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 | |
| CN115057936A (zh) | 异源二聚体多特异性抗体形式 | |
| CA2985700A1 (en) | T cell recruiting polypeptides based on cd3 reactivity | |
| CN115397852A (zh) | 工程化抗il-2抗体 | |
| Ahmed et al. | Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP2022540946A (ja) | コンジュゲーションのためのポリペプチド複合体及びその応用 | |
| WO2022262678A1 (zh) | 一种多特异性抗原结合蛋白及其应用 | |
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| TW202317636A (zh) | 靶向egfr及her3的雙特異性四價抗體 | |
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 | |
| CN117279951A (zh) | 抗5t4抗体及其用途 | |
| WO2020192648A1 (en) | Proteinaceous heterodimer and use thereof | |
| WO2025140489A1 (en) | Multispecific antibodies and uses thereof |